Artia Global Partners
Artia Global Partners reported 47 stocks worth $526M in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are ABVX (13.1%), INSM (11.9%) and TRVI (7.8%). Compared with Q1 2026, the fund opened new positions in ALKS, GH and ABSI, added to TRVI, BTSG and RVMD, trimmed ABVX, INSM and ALMS and sold out of LLY, ASND and ABBV.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  ABVX Abivax SA | $68.8M | 13.1% | 516K | −84K (−14%) | 4 of 8 | |
| 2 |  INSM Insmed Inc | $62.8M | 11.9% | 589K | −40K (−6%) | 8 of 8 | |
| 3 |  TRVI Trevi Therapeutics Inc | $41.2M | 7.8% | 2.2M | +197K (+10%) | 5 of 8 | |
| 4 |  BTSG Brightspring Health Svcs Inc | $36.1M | 6.9% | 517K | +464K (+862%) | 4 of 8 | |
| 5 |  RVMD Revolution Medicines Inc | $34.7M | 6.6% | 185K | +60K (+48%) | 8 of 8 | |
| 6 |  ARGX Argenx SE | $27.6M | 5.3% | 30K | No change | 8 of 8 | |
| 7 |  ALKS Alkermes PLC | $23.5M | 4.5% | 449K | New position | 1 of 8 | |
| 8 |  TVTX Travere Therapeutics Inc | $19.3M | 3.7% | 339K | +268K (+380%) | 6 of 8 | |
| 9 |  AZN Astrazeneca PLC Ord | $18.7M | 3.5% | 98K | +3,000 (+3%) | 2 of 8 | |
| 10 |  NAMS Newamsterdam Pharma Company | $17.1M | 3.3% | 504K | No change | 7 of 8 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
 LLY Eli Lilly & Co | $35.2M | 38K |
TERNS PHARMACEUTICALS INC | $5.5M | 105K |
 ASND Ascendis Pharma A/s | $4.1M | 18K |
 ABBV Abbvie Inc | $3.2M | 15K |
SOLENO THERAPEUTICS INC | $2.3M | 68K |
🔒 Free account: see all 8.
Options
valued at the underlying shares| Stock | Type | Value | Shares | Change |
|---|---|---|---|---|
 XBI Spdr Series Trust | Put | $15.8M | 100K | +100,000 |
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 14, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Artia Global Partners 13F FAQ
What does Artia Global Partners own?
Artia Global Partners reported 47 stocks worth $526M in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are ABVX (13.1%), INSM (11.9%) and TRVI (7.8%). The table above lists every position in the filing (the top 10 without an account).
What did Artia Global Partners buy and sell in Q2 2026?
Compared with Q1 2026: 7 new positions, 10 added to, 3 trimmed and 8 sold out. New positions include ALKS, GH and ABSI. It sold all of LLY, ASND and ABBV.
When will Artia Global Partners file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is Artia Global Partners's portfolio worth?
The Q2 2026 filing reports $526M in US stocks ($542M including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.